CN119546769A - 具有修饰的FC结构域的SIRP-α融合多肽 - Google Patents

具有修饰的FC结构域的SIRP-α融合多肽 Download PDF

Info

Publication number
CN119546769A
CN119546769A CN202380038570.7A CN202380038570A CN119546769A CN 119546769 A CN119546769 A CN 119546769A CN 202380038570 A CN202380038570 A CN 202380038570A CN 119546769 A CN119546769 A CN 119546769A
Authority
CN
China
Prior art keywords
domain
fusion polypeptide
modified
seq
sirpa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380038570.7A
Other languages
English (en)
Chinese (zh)
Inventor
J-P·沃尔克默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bitgen Biotech Co ltd
Original Assignee
Bitgen Biotech Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bitgen Biotech Co ltd filed Critical Bitgen Biotech Co ltd
Publication of CN119546769A publication Critical patent/CN119546769A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202380038570.7A 2022-03-24 2023-03-23 具有修饰的FC结构域的SIRP-α融合多肽 Pending CN119546769A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263323417P 2022-03-24 2022-03-24
US63/323,417 2022-03-24
PCT/US2023/064886 WO2023183892A1 (en) 2022-03-24 2023-03-23 Sirp-alpha fusion polypeptides with modified fc domains

Publications (1)

Publication Number Publication Date
CN119546769A true CN119546769A (zh) 2025-02-28

Family

ID=86054071

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380038570.7A Pending CN119546769A (zh) 2022-03-24 2023-03-23 具有修饰的FC结构域的SIRP-α融合多肽

Country Status (13)

Country Link
US (1) US20230365648A1 (https=)
EP (1) EP4499837A1 (https=)
JP (1) JP2025510774A (https=)
KR (1) KR20240162572A (https=)
CN (1) CN119546769A (https=)
AU (1) AU2023240361A1 (https=)
CA (1) CA3246192A1 (https=)
CL (1) CL2024002849A1 (https=)
CO (1) CO2024013909A2 (https=)
IL (1) IL315706A (https=)
JO (1) JOP20240212A1 (https=)
MX (1) MX2024011528A (https=)
WO (1) WO2023183892A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2816647T3 (es) 2012-01-17 2021-04-05 Univ Leland Stanford Junior Reactivos SIRP-alfa de alta afinidad
US10011660B2 (en) * 2012-04-30 2018-07-03 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
PL3575326T3 (pl) * 2012-12-17 2022-07-11 Pf Argentum Ip Holdings Llc Leczenie komórek chorobowych cd47+ z użyciem fuzji sirp alfa-fc
WO2016023040A1 (en) 2014-08-08 2016-02-11 Alexo Therapeutics International Sirp-alpha variant constructs and uses thereof
PL3180363T3 (pl) 2014-08-15 2020-02-28 Merck Patent Gmbh Białka fuzyjne immunoglobulin sirp-alfa
AU2016304794B2 (en) 2015-08-07 2021-07-15 ALX Oncology Inc. Constructs having a SIRP-alpha domain or variant thereof
CN116239698A (zh) * 2019-03-06 2023-06-09 江苏恒瑞医药股份有限公司 双功能融合蛋白及其医药用途
EP3976658A4 (en) * 2019-05-24 2023-06-07 Forty Seven, Inc. Regimes for co-administration of immunotherapeutic agents against c-kit and cd47
WO2020263830A1 (en) * 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use

Also Published As

Publication number Publication date
CO2024013909A2 (es) 2024-10-31
AU2023240361A1 (en) 2024-10-03
JOP20240212A1 (ar) 2024-09-29
CL2024002849A1 (es) 2025-05-23
KR20240162572A (ko) 2024-11-15
CA3246192A1 (en) 2023-09-28
WO2023183892A1 (en) 2023-09-28
IL315706A (en) 2024-11-01
EP4499837A1 (en) 2025-02-05
MX2024011528A (es) 2024-12-06
JP2025510774A (ja) 2025-04-15
US20230365648A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
JP6410712B2 (ja) Ｉｌ−６結合分子
KR20080005962A (ko) 인간 과립구 마크로파지 콜로니 자극 인자의 중화 항체
JP2024520666A (ja) Ｔ細胞エンゲージャ分子及びその使用
JP2024501403A (ja) ガンマ－デルタｔ細胞受容体に結合する抗体
US20240190983A1 (en) Novel TNFR2 Binding Molecules
KR20230170721A (ko) Bcma를 표적으로 하는 다중 특이성 항체
JP2025514939A (ja) Ｃｄ３／ｂｃｍａ／ｃｄ３８三重特異性抗体
JP2024542823A (ja) アンタゴニスト抗ｎｐｒ１抗体およびその使用方法
IL324435A (en) Anti-il1rap antibodies
US20250257113A1 (en) Multivalent sirp-alpha fusion polypeptides
EP4714975A1 (en) Antibody binding lilrb4 and cd3, and use thereof
CN119546769A (zh) 具有修饰的FC结构域的SIRP-α融合多肽
CN114867751A (zh) 4-1bb和ox40结合蛋白及相关组合物和方法、抗-4-1bb抗体、抗-ox40抗体
KR20170036505A (ko) 신규 항-tfpi 항체 및 이를 포함하는 조성물
CN113164601B (zh) 一种分离的抗原结合蛋白及其用途
JP2026506240A (ja) Ｍｕｃ１及びｃｄ１６ａ抗体ならびに使用方法
CN121175339A (zh) 抗fxi抗体及其用途
CA3111462A1 (en) Improved anti-flt3 antigen binding proteins
WO2021051351A1 (zh) 一种分离的抗原结合蛋白及其用途
EA043099B1 (ru) АНТИТЕЛА ПРОТИВ CD38 И СЛИТЫЕ БЕЛКИ С ОСЛАБЛЕННЫМ ИНТЕРФЕРОНОМ АЛЬФА-2b

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination